Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment
Authors
Keywords
-
Journal
NEUROLOGIC CLINICS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-08-23
DOI
10.1016/j.ncl.2023.07.006
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Roles and regulation of microglia activity in multiple sclerosis: insights from animal models
- (2023) Félix Distéfano-Gagné et al. NATURE REVIEWS NEUROSCIENCE
- Microglia Polarization From M1 to M2 in Neurodegenerative Diseases
- (2022) Shenrui Guo et al. Frontiers in Aging Neuroscience
- The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
- (2022) Carmen Tur et al. Multiple Sclerosis Journal
- Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease
- (2022) Zeyu Yin et al. Cell Death Discovery
- Approved and emerging Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia
- (2022) Alycia Hatashima et al. EXPERT OPINION ON PHARMACOTHERAPY
- Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
- (2022) Shazia Nakhoda et al. BRITISH JOURNAL OF HAEMATOLOGY
- The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review
- (2022) Michael Arustamyan et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Determining drug dose in the era of targeted therapies: playing it (un)safe?
- (2022) Sigrid S. Skånland et al. Blood Cancer Journal
- Updates and advances in multiple sclerosis neurotherapeutics
- (2022) Moein Amin et al. Neurodegenerative Disease Management
- Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
- (2022) Carmen Tur et al. JAMA Neurology
- Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: A review
- (2022) Sarah Peterson et al. Multiple Sclerosis and Related Disorders
- Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
- (2021) Martin Kaul et al. CTS-Clinical and Translational Science
- Ectopic lymphoid follicles in progressive multiple sclerosis: From patients to animal models
- (2021) Jiangshan Zhan et al. IMMUNOLOGY
- Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
- (2021) Daniel S Reich et al. LANCET NEUROLOGY
- Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)
- (2021) Timothy D. Owens et al. CTS-Clinical and Translational Science
- Molecular signature of slowly expanding lesions in progressive multiple sclerosis
- (2020) Katharina Jäckle et al. BRAIN
- Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis
- (2019) Jiaying Wang et al. Frontiers in Pharmacology
- Inhibition of Bruton’s Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer’s Disease
- (2019) James Keaney et al. Journal of Neuroimmune Pharmacology
- Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
- (2019) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers
- (2019) Andreas Becker et al. CTS-Clinical and Translational Science
- The Taxonomy of Covalent Inhibitors
- (2018) Alfred Tuley et al. BIOCHEMISTRY
- Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
- (2018) Ann E. Herman et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice
- (2018) Hye Yeon Nam et al. Journal of Neuroinflammation
- Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
- (2017) Philip A Thompson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
- (2016) Martin Dreyling et al. LANCET
- Dual Functions of Bruton's Tyrosine Kinase and Tec Kinase during Fc Receptor-Induced Signaling and Phagocytosis
- (2014) J. Jongstra-Bilen et al. JOURNAL OF IMMUNOLOGY
- Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity
- (2012) Sara J. Ireland et al. AUTOIMMUNITY
- Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice
- (2012) L. P. Kil et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started